Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity.

Hypertension (Dallas, Tex. : 1979) - 1 Mar 2008

Dietz Jessica D, Du Sarah, Bolten Charles W, Payne Maria A, Xia Chunsheng, Blinn James R, Funder John W, Hu Xiao

Abstract excerpt

Calcium channel blockers are widely used antihypertensives. Mineralocorticoid receptor antagonists are also used to treat hypertension and heart failure. We report here that a number of widely used dihydropyridine class calcium channel blockers are able to inhibit aldosterone-induced activation of mineralocorticoid receptor. These dihydropyridines varied in the extent of their effect on mineralocorticoid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenalectomy
Share to Aldosterone

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Calcium Channel Blockers

Share to Dose-Response Relationship, Drug

Share to Epithelial Sodium Channels

Share to Random Allocation

Share to Rats, Sprague-Dawley

Share to Receptors, Mineralocorticoid

Source

Identifiers

PMID: 18250364
DOI: 10.1161/HYPERTENSIONAHA.107.103580

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity.PMID 18250364Read ↗

The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family.Semantic proximity Read ↗

Structural basis for inhibition of a voltage-gated Ca2+ channel by Ca2+ antagonist drugs.Semantic proximity Read ↗

Pharmacology of L-type Calcium Channels: Novel Drugs for Old Targets?Semantic proximity Read ↗

Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.Semantic proximity Read ↗

The Renal Outer Medullary Potassium Channel Inhibitor, MK-7145, Lowers Blood Pressure, and Manifests Features of Bartter's Syndrome Type II Phenotype.Semantic proximity Read ↗

Distinct properties of amlodipine and nicardipine block of the voltage-dependent Ca2+ channels Cav1.2 and Cav2.1 and the mutant channels Cav1.2/dihydropyridine insensitive and Cav2.1/dihydropyridine sensitive.Semantic proximity Read ↗

Regulation of aldosterone secretion by Cav1.3.Semantic proximity Read ↗

Molecular determinants of drug binding and action on L-type calcium channels.Semantic proximity Read ↗

The mineralocorticoid receptor leads to increased expression of EGFR and T-type calcium channels that support HL-1 cell hypertrophy.Semantic proximity Read ↗

Antimineralocorticoid 11beta-substituted spirolactones exhibit androgen receptor agonistic activity: a structure function study.Semantic proximity Read ↗

Identification of steroid ligands able to inactivate the mineralocorticoid receptor harboring the S810L mutation responsible for a severe form of hypertension.Semantic proximity Read ↗

Transcriptional regulation of the human NA/K ATPase via the human mineralocorticoid receptorSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.